Table 2.
Cost of therapy and clinical impact by diagnostic strategy.
| NGS only | High-sensitivity PCR/IHC only | High-specificity PCR/IHC only | High-specificity AI only | High-sensitivity AI and NGS | High-specificity AI and NGS | High-sensitivity AI and high-sensitivity PCR/IHC | High-sensitivity AI and high-specificity PCR/IHC | |
|---|---|---|---|---|---|---|---|---|
| Total cost of diagnostic testing and first-line therapy | $3.13 | $3.05 | $2.76 | $2.75 | $3.03 | $3.12 | $3.00 | $2.72 |
| Cost of chemotherapy ± targeted therapy | $2.12 | $1.70 | $1.97 | $2.08 | $2.12 | $2.07 | $1.70 | $1.97 |
| Cost of immunotherapy | $0.90 | $1.31 | $0.76 | $0.67 | $0.88 | $0.94 | $1.29 | $0.74 |
| Cost of testing | $0.11 | $0.04 | $0.04 | $0.00 | $0.03 | $0.11 | $0.02 | $0.01 |
| Cost savings compared to reference scenario (NGS only) (absolute) | Reference | $0.07 | $0.36 | $0.37 | $0.10 | $0.01 | $0.12 | $0.40 |
| Cost savings compared to reference scenario (NGS only) (relative) | Reference | 2.3% | 11.6% | 11.9% | 3.2% | 0.2% | 3.9% | 12.9% |
| Weighted average time to treatment initiation | 12 | 4 | 4 | 0 | 3.0 | 11.4 | 1.6 | 1.2 |
| Percent of patients receiving results within guideline-recommended 10 working days (15) | 0% | 100% | 100% | 100% | 75% | 5% | 100% | 100% |
| Percent of patients receiving first-line therapy supported by KEYNOTE-177 | 100% | 81% | 91% | 97% | 80% | 97% | 81% | 91% |
Dollar values presented in billions. AI, artificial intelligence; IHC, immunohistochemistry; NGS, next-generation sequencing; PCR, polymerase chain reaction.